Global Market Direct’s pharmaceuticals report, “Ceregene, Inc. - Product Pipeline Review - 2013” provides data on the Ceregene, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Ceregene, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Ceregene, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
- Ceregene, Inc. - Brief Ceregene, Inc. overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Ceregene, Inc. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Ceregene, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Ceregene, Inc.’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products.
Reasons to buy
- Evaluate Ceregene, Inc.’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Ceregene, Inc. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Ceregene, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Ceregene, Inc.. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Ceregene, Inc. and identify potential opportunities in those areas.
Table Of Contents
Ceregene, Inc. - Product Pipeline Review - 2013 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Ceregene, Inc. Snapshot 5 Ceregene, Inc. Overview 5 Key Information 5 Key Facts 5 Ceregene, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Ceregene, Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Ceregene, Inc. - Pipeline Products Glance 10 Ceregene, Inc. Clinical Stage Pipeline Products 10 Phase II Products/Combination Treatment Modalities 10 Ceregene, Inc. - Early Stage Pipeline Products 11 Pre-Clinical Products/Combination Treatment Modalities 11 Ceregene, Inc. - Drug Profiles 12 CERE-110 12 Product Description 12 Mechanism of Action 12 RandD Progress 12 CERE-120 14 Product Description 14 Mechanism of Action 14 RandD Progress 14 CERE-135 17 Product Description 17 Mechanism of Action 17 RandD Progress 17 CERE-140 18 Product Description 18 Mechanism of Action 18 RandD Progress 18 Ceregene, Inc. - Pipeline Products by Route of Administration 19 Ceregene, Inc. - Pipeline Products By Mechanism of Action 20 Ceregene, Inc. - Recent Pipeline Updates 21 Ceregene, Inc. - Dormant Projects 23 Ceregene, Inc. - Locations And Subsidiaries 24 Head Office 24 Ceregene, Inc., Recent Developments 25 Ceregene, Inc.- Press Release 25 Apr 19, 2013: Ceregene Reports Top-line Data From Phase IIb Study Of CERE-120 For Treatment Of Parkinson's Disease 25 Mar 13, 2013: Ceregene And Alzheimer's Disease Cooperative Study Group Complete Enrollment For CERE-110 Phase II Trial 26 Oct 19, 2010: Ceregene Initiates Phase IIb Trial Of CERE-120 For Parkinson's Disease 27 Jun 22, 2010: The Michael J. Fox Foundation Awards $2.5 Million to Support Ceregene's New Phase 2 Neurturin Clinical Study for Parkinson's Disease 28 Apr 28, 2010: Ceregene Initiates New Phase I/II Trial Of CERE-120 For Parkinson's Disease 29 Financial Deals Landscape 31 Ceregene, Inc., Deals Summary 31 Ceregene, Inc., Pharmaceuticals and Healthcare, Deal Details 32 Venture Financing 32 Ceregene Secures US$11.5 Million In Series D Venture Financing 32 Ceregene Secures US$28.1 Million In Series C Financing 34 Partnerships 36 Ceregene Enters Into Agreement With Genzyme 36 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 39 Disclaimer 39
List of Tables
Ceregene, Inc., Key Information 5 Ceregene, Inc., Key Facts 5 Ceregene, Inc. - Pipeline by Indication, 2013 7 Ceregene, Inc. - Pipeline by Stage of Development, 2013 8 Ceregene, Inc. - Monotherapy Products in Pipeline, 2013 9 Ceregene, Inc. - Phase II, 2013 10 Ceregene, Inc. - Pre-Clinical, 2013 11 Ceregene, Inc. - Pipeline By Route of Administration, 2013 19 Ceregene, Inc. - Pipeline Products By Mechanism of Action, 2013 20 Ceregene, Inc. - Recent Pipeline Updates, 2013 21 Ceregene, Inc. - Dormant Developmental Projects,2013 23 Ceregene, Inc., Deals Summary 31 Ceregene Secures US$11.5 Million In Series D Venture Financing 32 Ceregene Secures US$28.1 Million In Series C Financing 34 Ceregene Enters Into Agreement With Genzyme 36
List of Figures
Ceregene, Inc. - Pipeline by Indication, 2013 7 Ceregene, Inc. - Pipeline by Stage of Development, 2013 8 Ceregene, Inc. - Monotherapy Products in Pipeline, 2013 9